E Fund Management (HK)’s BridgeBio Pharma BBIO Stock Holding History

E Fund Management (HK)’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22K	Buy	295 +75	+34%	+$5.25K	0.01%	300
2026 Q1	$16.3K	Buy	+220	New	+$15.9K	0.01%	230

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

E Fund Management (HK)'s BBIO Position: Q2 2026 in Review

E Fund Management (HK) increased its BridgeBio Pharma (BBIO) stake by 34% in Q2 2026, buying an estimated $5.25K and bringing the position to 295 shares worth $22K. The position accounts for 0.01% of the portfolio, ranked #300.

E Fund Management (HK) first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

E Fund Management (HK) held 295 shares of BridgeBio Pharma worth $22K as of Q2 2026.
E Fund Management (HK) bought 75 BridgeBio Pharma shares in Q2 2026, an estimated $5.25K.
BridgeBio Pharma made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #300 holding.
E Fund Management (HK) first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.